Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2016

  • ID: 3946422
  • Drug Pipelines
  • 294 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • BIOCAD
  • Cell Medica Limited
  • Genor BioPharma Co Ltd
  • Lipidor AB
  • NeuClone Pty Ltd
  • MORE
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2016

Summary

Our latest Pharmaceutical and Healthcare disease pipeline guide Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2016, provides an overview of the Plaque Psoriasis (Psoriasis Vulgaris) (Immunology) pipeline landscape.

Plaque psoriasis is a chronic, relapsing, inflammatory skin disorder. The frequency and intensity of psoriasis is affected by environmental factors such as smoking, sun exposure, alcoholism, and HIV infection. The symptoms of psoriasis include red patchy skin covered with silver scales, small scaling spots; dry cracked skin that may bleed; burning, itching, soreness, thickened, pitted or ridged nails; joint swelling and stiffening, and dandruff-like scaling over the scalp. Psoriasis is primarily diagnosed through an examination of the skin by dermatologist, as there are no blood tests or laboratory tests for a diagnosis of psoriasis.

Report Highlights

Our Pharmaceutical and Healthcare latest pipeline guide Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Plaque Psoriasis (Psoriasis Vulgaris) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 11, 20, 26, 13, 2, 11, 8 and 1 respectively for Plaque Psoriasis (Psoriasis Vulgaris).

Plaque Psoriasis (Psoriasis Vulgaris) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Plaque Psoriasis (Psoriasis Vulgaris) (Immunology).
- The pipeline guide reviews pipeline therapeutics for Plaque Psoriasis (Psoriasis Vulgaris) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Plaque Psoriasis (Psoriasis Vulgaris) (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Plaque Psoriasis (Psoriasis Vulgaris) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Plaque Psoriasis (Psoriasis Vulgaris) (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris) (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Plaque Psoriasis (Psoriasis Vulgaris) (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • BIOCAD
  • Cell Medica Limited
  • Genor BioPharma Co Ltd
  • Lipidor AB
  • NeuClone Pty Ltd
  • MORE
Introduction

Plaque Psoriasis (Psoriasis Vulgaris) Overview

Therapeutics Development

Plaque Psoriasis (Psoriasis Vulgaris) - Therapeutics under Development by Companies

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Products Glance

Plaque Psoriasis (Psoriasis Vulgaris) - Products under Development by Companies

Plaque Psoriasis (Psoriasis Vulgaris) - Companies Involved in Therapeutics Development

Plaque Psoriasis (Psoriasis Vulgaris) - Therapeutics Assessment

Drug Profiles

Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects

Plaque Psoriasis (Psoriasis Vulgaris) - Discontinued Products

Plaque Psoriasis (Psoriasis Vulgaris) - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Plaque Psoriasis (Psoriasis Vulgaris), H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Development by Companies, H2 2016 (Contd..1)

Number of Products under Development by Companies, H2 2016 (Contd..2)

Number of Products under Development by Companies, H2 2016 (Contd..3)

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Comparative Analysis by Unknown Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016 (Contd..1)

Products under Development by Companies, H2 2016 (Contd..2)

Products under Development by Companies, H2 2016 (Contd..3)

Products under Development by Companies, H2 2016 (Contd..4)

Products under Development by Companies, H2 2016 (Contd..5)

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by AbbVie Inc, H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by AbGenomics International, Inc., H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Almirall, S.A., H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Alteogen Inc., H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Amgen Inc., H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by AstraZeneca Plc, H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Avexxin AS, H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by BIOCAD, H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Biocon Limited, H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Bionovis SA, H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Boehringer Ingelheim GmbH, H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Bristol-Myers Squibb Company, H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by CalciMedica, Inc., H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Can-Fite BioPharma Ltd., H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Cell Medica Limited, H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Cellceutix Corporation, H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Coherus BioSciences, Inc., H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Eli Lilly and Company, H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Exicure, Inc., H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Forward Pharma A/S, H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Genor BioPharma Co Ltd, H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by GlaxoSmithKline Plc, H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Idera Pharmaceuticals, Inc., H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Johnson & Johnson, H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Kadmon Corporation, LLC, H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Kang Stem Biotech Co., Ltd., H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by KPI Therapeutics, Inc., H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by LEO Pharma A/S, H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Lipidor AB, H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Lupin Limited, H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Lycera Corp., H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Maruho Co., Ltd., H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by MetrioPharm AG, H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Momenta Pharmaceuticals, Inc., H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Mycenax Biotech Inc., H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by NeuClone Pty Ltd, H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Novartis AG, H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Oncobiologics, Inc., H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Pfizer Inc., H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Promius Pharma, LLC, H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Protalix BioTherapeutics, Inc., H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Sandoz International GmbH, H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Shanghai Celgen Bio-Pharmaceutical Co., Ltd., H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by TheraMAB LLC, H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Therapeutic Proteins International, LLC, H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by UCB S.A., H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by XBiotech Inc, H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Ziarco Pharma Ltd, H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects, H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..1), H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..2), H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..3), H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..4), H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..5), H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..6), H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..7), H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Discontinued Products, H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Discontinued Products (Contd..1), H2 2016

List of Figures

Number of Products under Development for Plaque Psoriasis (Psoriasis Vulgaris), H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
AbbVie Inc
AbGenomics International, Inc.
Almirall, S.A.
Alteogen Inc.
Amgen Inc.
AstraZeneca Plc
Avexxin AS
BIOCAD
Biocon Limited
Bionovis SA
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
CalciMedica, Inc.
Can-Fite BioPharma Ltd.
Cell Medica Limited
Cellceutix Corporation
Coherus BioSciences, Inc.
Eli Lilly and Company
Epirus Biopharmaceuticals, Inc.
Exicure, Inc.
Forward Pharma A/S
Genor BioPharma Co Ltd
GlaxoSmithKline Plc
Idera Pharmaceuticals, Inc.
Johnson & Johnson
Kadmon Corporation, LLC
Kang Stem Biotech Co., Ltd.
KPI Therapeutics, Inc.
LEO Pharma A/S
Lipidor AB
Lupin Limited
Lycera Corp.
Maruho Co., Ltd.
MetrioPharm AG
Mitsubishi Tanabe Pharma Corporation
Momenta Pharmaceuticals, Inc.
Mycenax Biotech Inc.
NeuClone Pty Ltd
Novartis AG
Oncobiologics, Inc.
Pfizer Inc.
Promius Pharma, LLC
Protalix BioTherapeutics, Inc.
Provectus Biopharmaceuticals, Inc.
Sandoz International GmbH
Shanghai Celgen Bio-Pharmaceutical Co., Ltd.
Sucampo Pharmaceuticals, Inc.
Sun Pharma Advanced Research Company Ltd.
Takeda Pharmaceutical Company Limited
TheraMAB LLC
Therapeutic Proteins International, LLC
UCB S.A.
Valeant Pharmaceuticals International, Inc.
XBiotech Inc
Ziarco Pharma Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll